Monday, November 07, 2022 9:49:07 PM
dstock07734,
What is really amazing is what Linda Powers has up her sleeve. She isn’t talking about some things going on in research with others that had received some previous attention in the past. The key to understanding where things might be heading is in what is not being talked about or even hinted at any more with this company. So so much to be shared at the right time.
Their research is much further ahead of being able to capitalize on it because of “the process” right now. Once manufacturing gets taken care of, that trump card will push regulators faster and further ahead so costs can be driven down than many have thought possible because of the concept of “sameness” and specific biomarkers related to survival. This is going to be fun to watch unfold. First things first. It’s Dr. Linda Liau time. Best wishes.
What is really amazing is what Linda Powers has up her sleeve. She isn’t talking about some things going on in research with others that had received some previous attention in the past. The key to understanding where things might be heading is in what is not being talked about or even hinted at any more with this company. So so much to be shared at the right time.
Their research is much further ahead of being able to capitalize on it because of “the process” right now. Once manufacturing gets taken care of, that trump card will push regulators faster and further ahead so costs can be driven down than many have thought possible because of the concept of “sameness” and specific biomarkers related to survival. This is going to be fun to watch unfold. First things first. It’s Dr. Linda Liau time. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
